Article
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
Journal of hepatology - 1 May 2013
Pol Stanislas, Aerssens Jeroen, Zeuzem Stefan, Andreone Pietro, Lawitz Eric J, Roberts Stuart, Younossi Zobair, Foster Graham R, Focaccia Roberto, Horban Andrzej, Pockros Paul J, Van Heeswijk Rolf P G, De Meyer Sandra, Luo Don, Botfield Martyn, Beumont Maria, Picchio Gaston
Abstract excerpt
BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naïve patients treated with peginterferon/ribavirin (PegIFN/RBV). This subanalysis of the REALIZE study evaluated the impact of IL28B polymorphisms on sustained virologic response (SVR) in telaprevir-treated, HCV genotype 1-infected patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
